4.6 Review

Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group

Related references

Note: Only part of the references are listed.
Article Medical Laboratory Technology

HER2 Testing in Endometrial Serous Carcinoma Time for Standardized Pathology Practice to Meet the Clinical Demand

Natalia Buza

Summary: Endometrial serous carcinoma is an aggressive subtype of endometrial cancer with the highest rate of recurrence and mortality. Recent studies have shown prolonged progression-free survival in advanced-stage and recurrent HER2-positive endometrial serous carcinoma when trastuzumab is added to the standard chemotherapy regimen. Pathologists play a crucial role in recognizing the unique characteristics of HER2 protein expression and gene amplification in these tumors to ensure successful clinical outcomes.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2021)

Article Oncology

Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion

Angela Santoro et al.

Summary: The study found that MELF thorn tumors have a higher risk of lymph node metastasis compared to MELF- tumors, and the morphological recognition of the MELF pattern is more reliable in predicting nodal involvement in EEC than immunohistochemical and molecular markers.
Article Obstetrics & Gynecology

Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer

Young Shin Chung et al.

Summary: The study evaluated the prognostic significance of the Proactive Molecular Risk Classifier for Endometrial Cancer in fertility-sparing management, revealing that mismatch repair status could be used as a predictive biomarker for selecting patients who could benefit from hormone therapy. These findings suggest early stratification and risk assignment to direct care, but need validation in larger studies.

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2021)

Article Pathology

Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features

Amy Joehlin-Price et al.

Summary: This study evaluated the prognostic impact of molecular classification on FIGO grade 3 endometrioid endometrial carcinoma, using POLE mutation analysis and immunohistochemistry. The POLE mutation group and multiple classifier group showed excellent clinical outcomes, while the p53-ab group showed the worst clinical outcomes. Overall, there was no correlation between molecular grouping and tumor immunophenotypic findings.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)

Review Oncology

Recent advances in Lynch syndrome

Xi Li et al.

Summary: Lynch syndrome is a common hereditary cancer syndrome characterized by mutations in DNA mismatch repair genes, with colorectal cancer and endometrial cancer being the most common types of cancer associated with this syndrome. Recent advancements have improved our understanding of the disease and have led to more efficient diagnostic and treatment strategies.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

Article Obstetrics & Gynecology

Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity

Douglas Rottmann et al.

Summary: This study evaluated the concordance of HER2 status between endometrial biopsy/curettage and subsequent hysterectomy specimens in endometrial serous carcinoma, finding a lower concordance rate compared to breast cancer, likely due to intratumoral heterogeneity and differences in sampling methods.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)

Article Obstetrics & Gynecology

HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting

Natalia Buza

Summary: Anti-HER2 therapy has shown effectiveness in treating advanced stage and recurrent endometrial serous carcinoma by significantly prolonging progression-free and overall survival when combined with chemotherapy. There is an increasing clinical demand for HER2 testing in pathology laboratories. A specific HER2 testing algorithm has been proposed based on recent clinical trials, serving as a basis for future recommendations, but further studies are needed for refinement and adjustment of criteria to maximize the clinical benefit.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)

Article Pathology

Relationship between morular metaplasia and squamous differentiation in endometrial carcinoma

Antonio Travaglino et al.

Summary: Our study on morular metaplasia (MM) in endometrial lesions shows that mixed MM/SD cases exhibit squamous differentiation (SD) mostly within MM areas, while conventional SD cases show a direct transition from glandular epithelium to SD. Immunohistochemistry results also demonstrate distinct expression patterns between the two types of cases. Further research is needed to define the nature of MM and its relationship with SD.

PATHOLOGY RESEARCH AND PRACTICE (2021)

Review Oncology

Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors

Julie Leclerc et al.

Summary: Microsatellite instability (MSI) is a hallmark of Lynch syndrome (LS)-related tumors, but it is not exclusive to LS, as most MSI/mismatch repair-deficient (dMMR) tumors are sporadic. Advances in diagnostic and screening strategies have evolved in recent years, focusing on identifying LS patients and distinguishing LS-related from sporadic MSI tumors. Discussions on pitfalls associated with current strategies aim to improve LS diagnosis and prevent inappropriate clinical management.

CANCERS (2021)

Review Oncology

Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification

Angela Santoro et al.

Summary: This study evaluated the clinico-pathological significance of TCGA molecular groups and SWI/SNF protein expression in undifferentiated/dedifferentiated endometrial carcinoma (UEC/DDEC). The findings suggest that POLE-mutant cases exhibit a good prognosis, while SWI/SNF-deficient cases have a poor prognosis. Other TCGA molecular subtypes appear to have an intermediate biological behavior.

GYNECOLOGIC ONCOLOGY (2021)

Article Pathology

The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

Willem Jan van Weelden et al.

Summary: There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC), but this study identified cutoff values with the strongest prognostic impact and proposed a classification based on these values to predict distinct clinical outcomes.

HUMAN PATHOLOGY (2021)

Article Pathology

Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study

Natalia Buza et al.

Summary: A new set of HER2 scoring criteria specific to endometrial serous carcinoma has been proposed based on recent successful clinical trials and pathologic studies. The study showed moderate to substantial interobserver agreement rates among gynecologic pathologists, supporting the reproducibility of the proposed criteria and strengthening the foundation for establishing endometrial cancer-specific HER2 scoring guidelines in the future.

MODERN PATHOLOGY (2021)

Article Pathology

ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al.

Summary: A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines. Given the large body of literature on the management of endometrial carcinoma published since 2014, the guidelines were updated by ESGO/ESTRO/ESP. The guidelines cover various aspects of endometrial carcinoma care and are evidence-based.

VIRCHOWS ARCHIV (2021)

Article Obstetrics & Gynecology

Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of Copy-number Low Tumors

Vivienne T. Meljen et al.

Summary: The study evaluated morphologic patterns, mutational profiles, and beta-catenin immunohistochemistry in copy-number low endometrial adenocarcinomas. CNL EAs demonstrated diverse morphologies and molecular profiles, with beta-catenin IHC being a sensitive and specific marker for CTNNB1 mutations. Notably, squamous differentiation was significantly associated with CTNNB1 mutations in CNL EAs.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)

Review Medicine, General & Internal

An Emerging Anti-p16 Antibody-BC42 Clone as an Alternative to the Current E6H4 for Use in the Female Genital Tract Pathological Diagnosis: Our Experience and a Review on p16ink4a Functional Significance, Role in Daily-Practice Diagnosis, Prognostic Potential, and Technical Pitfalls

Giuseppe Angelico et al.

Summary: The study discussed the diagnostic applications of p16 IHC in gynecological pathology using the novel anti-p16 INK4a antibody (clone BC42) and compared it to the traditional E6H4 clone. Results showed concordant staining quality of both clones on all tested neoplastic tissues, suggesting that the novel antibody is a reliable alternative for use in gynecological neoplasms.

DIAGNOSTICS (2021)

Review Oncology

New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines

Angela Santoro et al.

Summary: Histopathological classification of endometrial carcinoma divides tumors into low-grade and high-grade groups, while TCGA identifies four molecular categories: POLE/ultramutated, microsatellite instability (MSI)/hypermutated, copy-number low/endometrioid, and copy-number high/serous-like. The classification based on tumor morphology and molecular features plays a crucial role in prognosis and guiding treatment strategies.

CANCERS (2021)

Article Obstetrics & Gynecology

Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma

Danielle C. Costigan et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)

Article Obstetrics & Gynecology

Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens

Anna Plotkin et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)

Article Oncology

Interpretation of somatic POLE mutations in endometrial carcinoma

Alicia Leon-Castillo et al.

JOURNAL OF PATHOLOGY (2020)

Editorial Material Pathology

Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development

Gian Franco Zannoni et al.

VIRCHOWS ARCHIV (2020)

Article Obstetrics & Gynecology

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility

Martin Kobel et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)

Article Obstetrics & Gynecology

Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting Prognosis in Endometrial Cancer

Yue Wang et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)

Article Oncology

Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers

Marisa R. Moroney et al.

GYNECOLOGIC ONCOLOGY (2019)

Article Obstetrics & Gynecology

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer

Umran Kucukgoz Gulec et al.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2019)

Review Oncology

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review

Willem Jan van Weelden et al.

FRONTIERS IN ONCOLOGY (2019)

Review Oncology

TCGA molecular groups of endometrial cancer: Pooled data about prognosis

Antonio Raffone et al.

GYNECOLOGIC ONCOLOGY (2019)

Review Biochemistry & Molecular Biology

Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?

Ryan M. Marquardt et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Review Oncology

Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers

Yves Lecarpentier et al.

FRONTIERS IN ONCOLOGY (2019)

Article Oncology

Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma

Stefano Indraccolo et al.

CLINICAL CANCER RESEARCH (2019)

Article Pathology

Immunohistochemical Nuclear Expression of -Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer

Antonio Travaglino et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)

Article Oncology

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma

Aline Talhouk et al.

CLINICAL CANCER RESEARCH (2019)

Article Oncology

International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013

Joannie Lortet-Tieulent et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

Article Oncology

International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013

Joannie Lortet-Tieulent et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

Article Pathology

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups

Tjalling Bosse et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)

Review Oncology

The roles of pathology in targeted therapy of women with gynecologic cancers

Rajmohan Murali et al.

GYNECOLOGIC ONCOLOGY (2018)

Article Oncology

Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers

Giacomo Corrado et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)

Article Gastroenterology & Hepatology

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

Takeru Wakatsuki et al.

JOURNAL OF GASTROENTEROLOGY (2018)

Article Biochemistry & Molecular Biology

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim et al.

NATURE MEDICINE (2018)

Article Oncology

L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

Felix K. F. Kommoss et al.

BRITISH JOURNAL OF CANCER (2018)

Review Multidisciplinary Sciences

The therapeutic significance of mutational signatures from DNA repair deficiency in cancer

Jennifer Ma et al.

NATURE COMMUNICATIONS (2018)

Article Oncology

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions

Mari Kylleso Halle et al.

BRITISH JOURNAL OF CANCER (2018)

Review Biochemistry & Molecular Biology

Wnt signaling in cancer

T. Zhan et al.

ONCOGENE (2017)

Article Oncology

The genetic landscape of endometrial clear cell carcinomas

Deborah F. DeLair et al.

JOURNAL OF PATHOLOGY (2017)

Review Obstetrics & Gynecology

Molecular mechanism of estrogen-estrogen receptor signaling

Pelin Yasar et al.

REPRODUCTIVE MEDICINE AND BIOLOGY (2017)

Article Biochemistry & Molecular Biology

Comprehensive Analysis of Hypermutation in Human Cancer

Brittany B. Campbell et al.

Article Pathology

Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification

Anthony N. Karnezis et al.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2017)

Review Pharmacology & Pharmacy

Drug-biomarker co-development in oncology-20 years and counting

Julianne D. Twomey et al.

DRUG RESISTANCE UPDATES (2017)

Article Oncology

Integrated Molecular Characterization of Uterine Carcinosarcoma

Andrew D. Cherniack et al.

CANCER CELL (2017)

Review Immunology

Coinhibitory Pathways in Immunotherapy for Cancer

Susanne H. Baumeister et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)

Article Medicine, Research & Experimental

The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression

Jiandong Chen

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)

Review Oncology

A panoply of errors: polymerase proofreading domain mutations in cancer

Emily Rayner et al.

NATURE REVIEWS CANCER (2016)

Article Pathology

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

Martin Kobel et al.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2016)

Article Gastroenterology & Hepatology

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study

Enric Domingo et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)

Meeting Abstract Oncology

PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy

T. J. Herzog et al.

GYNECOLOGIC ONCOLOGY (2015)

Article Obstetrics & Gynecology

Should Endometrial Clear Cell Carcinoma be Classified as Type II Endometrial Carcinoma?

Hyo Sook Bae et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2015)

Article Oncology

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer

David N. Church et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)

Article Pathology

In-depth molecular profiling of the biphasic components of uterine carcinosarcomas

Melissa K. McConechy et al.

JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)

Article Pathology

Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer

Anne M. Mills et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)

Article Cell & Tissue Engineering

Wnt/Catenin Signaling in Adult Stem Cell Physiology and Disease

Alexander Ring et al.

STEM CELL REVIEWS AND REPORTS (2014)

Article Oncology

Marked Heterogeneity of HER2/NEU Gene Amplification in Endometrial Serous Carcinoma

Natalia Buza et al.

GENES CHROMOSOMES & CANCER (2013)

Article Biochemistry & Molecular Biology

DNA polymerase ? and exonuclease domain mutations in endometrial cancer

David N. Church et al.

HUMAN MOLECULAR GENETICS (2013)

Article Multidisciplinary Sciences

Integrated genomic characterization of endometrial carcinoma

Gad Getz et al.

NATURE (2013)

Article Obstetrics & Gynecology

HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas

Federica Guzzo et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)

Article Pathology

Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma

Fei Bao et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)

Article Gastroenterology & Hepatology

Microsatellite Instability in Colorectal Cancer

C. Richard Boland et al.

GASTROENTEROLOGY (2010)

Review Biochemistry & Molecular Biology

GSK3: a multifaceted kinase in Wnt signaling

Dianqing Wu et al.

TRENDS IN BIOCHEMICAL SCIENCES (2010)

Article Cell Biology

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

Magali Olivier et al.

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)

Review Cell Biology

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

Bryan T. MacDonald et al.

DEVELOPMENTAL CELL (2009)

Review Oncology

p21 in cancer: intricate networks and multiple activities

Tarek Abbas et al.

NATURE REVIEWS CANCER (2009)

Review Neurosciences

L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth

Ralf S. Schmid et al.

CURRENT OPINION IN NEUROBIOLOGY (2008)

Review Cell Biology

Transcriptional control of human p53-regulated genes

Todd Riley et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)

Review Cell Biology

The many ways of Wnt in cancer

Paul Polakis

CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)

Review Developmental Biology

Frizzled/RYK mediated signalling in axon guidance

Paola Bovolenta et al.

DEVELOPMENT (2006)

Review Multidisciplinary Sciences

Convergence of Wnt, β-catenin, and cadherin pathways

WJ Nelson et al.

SCIENCE (2004)